Spring­Works eyes US fil­ing for MEK in­hibitor af­ter pos­i­tive PhI­Ib da­ta in rare dis­ease

Spring­Works Ther­a­peu­tics has un­veiled pos­i­tive da­ta from a mid-stage tri­al of its drug can­di­date for neu­rofi­bro­mato­sis type 1 (NF1) as­so­ci­at­ed plex­i­form neu­rofi­bro­mas (PN), paving the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER